AI tool to predict outcomes in metastatic lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called non-small cell lung cancer (NSCLC).
- Your cancer must be stage IV (advanced, not able to be cured with local treatments like surgery or radiation).
- You need to have received at least one cycle of immunotherapy alone or in combination with chemotherapy.
- You must be available for follow-up visits as part of standard care.
- You cannot have other types of lung cancer (like small cell lung cancer).
- You should not be enrolled in other clinical trials with different drug combinations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an artificial intelligence (AI) tool to look at your scans and health information to better predict whether lung cancer might spread to the brain and how the disease may progress. It aims to help doctors make more personalized treatment decisions.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This trial tests whether artificial intelligence can help doctors plan better treatment for non-small cell lung cancer (NSCLC). A team of specialists will use AI tools alongside their usual approach to see if it improves care and safety.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
This trial tests an artificial intelligence platform that helps doctors predict if lymph nodes in the chest contain cancer during a routine ultrasound procedure. It aims to make staging more accurate for people with suspected or confirmed non-small cell lung cancer.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.